Media + News

Featured
Being a Therapist On a Psychedelic Clinical Trial: What Is It Like?
Being a Therapist On a Psychedelic Clinical Trial: What Is It Like?
MDMA Denied: Why This Is Just the Beginning for the Sector
MDMA Denied: Why This Is Just the Beginning for the Sector
Delivering Effective Psychedelic Clinical Trials: Overcoming Challenges for Meaningful Outcomes
Delivering Effective Psychedelic Clinical Trials: Overcoming Challenges for Meaningful Outcomes
From Analysis to Action: Implementing lessons from FDA AdComm's MDMA review
From Analysis to Action: Implementing lessons from FDA AdComm's MDMA review
To therapise or not to therapise, is that the question?
To therapise or not to therapise, is that the question?
Preparing Psychedelic Therapy Training: A New-Joiner’s Experience of Clerkenwell Health
Preparing Psychedelic Therapy Training: A New-Joiner’s Experience of Clerkenwell Health
Highlights from our Training Programme Q&A Event
Highlights from our Training Programme Q&A Event
Treatment-resistant depression and emerging treatments
Treatment-resistant depression and emerging treatments
Tackling post-traumatic stress disorder (PTSD) with methylone
Tackling post-traumatic stress disorder (PTSD) with methylone
How to join a psychedelic clinical trial?
How to join a psychedelic clinical trial?
Will the UK’s ambitious life sciences investment power-up the psychedelic sector? 
Will the UK’s ambitious life sciences investment power-up the psychedelic sector? 
Clerkenwell Health and Cognitive Research Corporation Partner to Facilitate Transatlantic Psychedelic Research
Clerkenwell Health and Cognitive Research Corporation Partner to Facilitate Transatlantic Psychedelic Research
Why Reinvent the Wheel When You Can Amplify the Effects of Existing Therapy Models?
Why Reinvent the Wheel When You Can Amplify the Effects of Existing Therapy Models?
Transatlantic Psychedelics: drug developers without borders
Transatlantic Psychedelics: drug developers without borders
The Weakest Link: Poor quality therapists a risk to psychedelic trial success
The Weakest Link: Poor quality therapists a risk to psychedelic trial success
Working with psychedelics: George McBride
Working with psychedelics: George McBride
Regulatory approval in under 8 weeks possible for psychedelic trials in the UK
Regulatory approval in under 8 weeks possible for psychedelic trials in the UK
Rising tides lift all ships: What attracts drug developers to the UK’s psychedelic ecosystem?
Rising tides lift all ships: What attracts drug developers to the UK’s psychedelic ecosystem?
Working with psychedelics: Laure Nolet
Working with psychedelics: Laure Nolet
The Race for Data Exclusivity
The Race for Data Exclusivity
How It Works: ‘Setting’
How It Works: ‘Setting’
Clerkenwell Health Taps Top Academics and Expands Pan-European Scientific Advisory Board
Clerkenwell Health Taps Top Academics and Expands Pan-European Scientific Advisory Board
Why we’re opening Europe’s first commercial psychedelic research facility
Why we’re opening Europe’s first commercial psychedelic research facility
Clerkenwell Health launches new therapist free training programme to remove bottlenecks in the psychedelic industry
Clerkenwell Health launches new therapist free training programme to remove bottlenecks in the psychedelic industry
Working with psychedelics: Clare Knight
Working with psychedelics: Clare Knight
Working with psychedelics: Bex Harding
Working with psychedelics: Bex Harding
Renowned British healthcare leader joins Clerkenwell Health as Therapy Lead
Renowned British healthcare leader joins Clerkenwell Health as Therapy Lead
Thou Shalt Not Pass: Solving the Psychedelic Specialist Therapist Bottleneck
Thou Shalt Not Pass: Solving the Psychedelic Specialist Therapist Bottleneck
The Gold Standard for Psychedelic-Assisted Therapy?
The Gold Standard for Psychedelic-Assisted Therapy?
Is the UK an ideal location to run psychedelic trials?
Is the UK an ideal location to run psychedelic trials?